VIIBRYD Drug Patent Profile

When do Viibryd patents expire, and when can generic versions of Viibryd launch?

Viibryd is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Viibryd

A generic version of VIIBRYD was approved as vilazodone hydrochloride by TEVA PHARMS USA on September 30^th, 2019.

Summary for VIIBRYD

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	157
Clinical Trials:	16
Patent Applications:	343
Drug Prices:	Drug price information for VIIBRYD
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIIBRYD
What excipients (inactive ingredients) are in VIIBRYD?	VIIBRYD excipients list
DailyMed Link:	VIIBRYD at DailyMed

See drug prices for VIIBRYD

See drug sales revenues for VIIBRYD

Recent Clinical Trials for VIIBRYD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Forest Laboratories	Phase 1
New York State Psychiatric Institute	Phase 4
Forest Laboratories	Phase 3

See all VIIBRYD clinical trials

Paragraph IV (Patent) Challenges for VIIBRYD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIIBRYD	Tablets	vilazodone hydrochloride	10 mg, 20 mg, and 40 mg	022567	5	2015-01-21

US Patents and Regulatory Information for VIIBRYD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-001	Jan 21, 2011	AB	RX	Yes	Yes
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-002	Jan 21, 2011	AB	RX	Yes	No
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-003	Jan 21, 2011	AB	RX	Yes	No

Expired US Patents for VIIBRYD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-001	Jan 21, 2011	5,532,241
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-003	Jan 21, 2011	5,532,241
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-002	Jan 21, 2011	5,532,241

International Patents for VIIBRYD

See the table below for patents covering VIIBRYD around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	153663
Australia	679774
Australia	7424494
Brazil	1100891
Canada	2133152	PIPERIDINES ET PIPERAZINES AVEC AFFINITE POUR RECEPTEURS 5-HT (PIPERIDINES AND PIPERAZINES WITH AFFINITY FOR 5-HT RECEPTORS)
China	1056610
China	1106811

VIIBRYD (vilazodone) Market Dynamics and Financial Trajectory: Pricing, Demand, Competition, Patent/Generic Pressure, and Revenue Exposure

Last updated: June 19, 2026

Executive summary

VIIBRYD (vilazodone) is a branded SSRI/serotonin receptor modulator in the US whose market dynamics have shifted toward sustained share loss driven by competitive antidepressants, payor pressure on branded utilization, and the structural difficulty of competing against lower-cost generics and rebate-backed brands. From a patent and exclusivity standpoint, vilazodone is no longer protected by primary new-drug exclusivity in the US, creating a durable risk environment for further net-sales erosion, formulary displacement, and shrinking prescriber mindshare. Commercial performance has therefore trended toward late-cycle branded decline rather than sustained growth.

What market dynamics shape VIIBRYD (vilazodone) demand in the US?

VIIBRYD’s demand has historically depended on three levers that increasingly favor competitors: net pricing (after rebates), formulary access, and prescriber substitution. In modern US antidepressant markets, branded drugs with no long-term exclusivity advantage tend to face faster utilization compression once generics and other branded options are entrenched in formularies.

Net price and rebate dynamics

• Antidepressant formularies in the US rely heavily on rebate contracting and step therapy. Branded products typically trade net price for formulary continuity, and net sales fall when rebates rise or when payors tighten preferred tiers.
• As generic antidepressants consolidate share across major classes (SSRIs, SNRIs), branded SSRI-adjacent products must outperform on tolerability perceptions or niche efficacy narratives to retain higher-cost patient access.

Formulary positioning and switching

• VIIBRYD is positioned as a once-daily oral antidepressant. In antidepressant classes, payors commonly encourage switching to preferred generics or preferred brands (based on formulary tiering and rebate rate).
• Switching risk is high because prescribers can revert to established generics with predictable cost and coverage profiles.

Patient access constraints

• Segment dynamics matter: early lines of therapy are usually managed by payor protocols favoring lower-cost options; branded uptake tends to concentrate in patients with prior response or intolerance to other agents.

How has VIIBRYD’s financial trajectory evolved since launch?

Late-stage branded antidepressants in the US typically show:

• Peak net sales early, then a drift downward as generics take share and payor access tightens.
• Volatility driven more by formulary wins and rebate negotiations than by product differentiation.

For VIIBRYD, the commercial pattern aligns with a mature branded timeline: ongoing share pressure from lower-cost alternatives and no pathway to regain broad market dominance after generic substitution became feasible. The practical effect is sustained net-sales erosion and reduced investment priority versus newer branded launches in competitive CNS categories.

Revenue drivers that still matter

• Continued prescriber retention among clinicians familiar with vilazodone.
• Coverage exceptions and prior authorization workflows that support continued access in a subset of patients.
• Short-lived improvement windows tied to managed-care cycle changes, rebate re-contracting, or formulary exceptions.

What caps upside for VIIBRYD

• Lack of a long-term exclusivity lever in the core market.
• Competitive density in depression: multiple preferred generics and newer branded CNS agents.
• Pharmacy benefit manager incentives that favor lower WAC-to-net spreads.

What generic entry risks exist for VIIBRYD (vilazodone)?

Generic risk is structural for vilazodone because it is a small-molecule antidepressant and the branded lifecycle naturally transitions to generic competition absent durable, broad formulation or method-of-use exclusivity.

Paragraph IV and FDA exclusivity risk profile

• Small-molecule depressants typically face rapid generic challenge once Orange Book-listed patents are actionable.
• Even without active Paragraph IV litigation at any given moment, the presence of generic products and the lack of “evergreening” coverage can pressure branded usage.

Bottlenecks that still affect generic penetration

Generic substitution can be delayed by:

• Residual brand protections tied to remaining, narrower patents.
• Rebate and formulary tactics that keep the branded drug on preferred tiers longer than the lowest-cost option.
• Manufacturing or supply constraints in generic markets, though these are episodic.

What patents protect VIIBRYD (vilazodone) and when do they expire?

A complete, accurate patent-by-patent exclusivity and expiration map requires Orange Book listings and the associated listed patent numbers, assignees, filing histories, expiration dates, and any pediatric exclusivity or terminal disclaimer effects. This dataset is not available in the prompt, and the analysis cannot be made accurate without those specific entries.

What is the Orange Book status of VIIBRYD?

A correct Orange Book status summary requires:

• Each Orange Book listed patent for vilazodone products (drug product, active ingredient, dosage form)
• Expiration dates and exclusivity categories (NCE, 505(b)(2), pediatric exclusivity where applicable)
• “Notified” generic applications and any Hatch-Waxman carveouts

This information is not included in the prompt, so an accurate status write-up cannot be produced.

Which companies compete with VIIBRYD and how does VIIBRYD compare on positioning?

The relevant competitive set is broad across antidepressants. In practice, VIIBRYD competes for utilization against:

• Preferred SSRI generics (often first-line under PBM formularies)
• Preferred SNRI and other branded options where payors seek limited differentiation categories
• Other CNS agents where deprescribing and switching protocols are common

How VIIBRYD’s differentiation is typically evaluated

• Tolerability and side-effect profiles compared to SSRIs and SNRIs
• Patient adherence linked to once-daily dosing
• Clinician familiarity and historical patient response

In managed care, these “clinical differentiation” factors must translate into net formulary value. If VIIBRYD cannot secure a favorable net cost position, utilization declines even when clinicians prefer it.

What FDA regulatory pathway governs VIIBRYD, and does it affect competition timing?

A product’s FDA reference pathway can influence exclusivity scope and the mechanics of generic approvals, but a correct analysis requires:

• The original NDA/505(b)(2) pathway details
• Applicable exclusivity listings and patent-claim coverage
• Any later supplemental approvals that might alter protection scope

Those specifics are not in the prompt, so a definitive regulatory-timing analysis cannot be provided.

How do patent litigation and settlements affect VIIBRYD’s sales?

Hatch-Waxman patent litigation affects branded sales when:

• A court entry or settlement delays generic launch.
• A settlement forces licensing or agreed launch dates.
• A stay of FDA approval blocks generic market entry.

This write-up requires litigation docket facts, parties, asserted patents, and settlement terms. Without case identifiers and docket dates, the effect cannot be stated accurately.

How does formulation and method-of-use IP impact VIIBRYD commercialization?

Even after generic chemical entity approvals become feasible, formulation or method-of-use patents can:

• Restrict substitution to specific dosage forms or labeling claims
• Encourage design-around development by generics
• Extend branded market time if claims are broad enough and enforceable

A complete analysis requires the Orange Book patent list and the underlying patent claims tied to vilazodone products. That dataset is not provided.

Revenue exposure: how much financial risk does VIIBRYD carry to a portfolio?

Portfolio exposure depends on:

• Current net sales run-rate
• Payer mix and exposure to PBM policy changes
• Contracted rebate structure and inventory dynamics
• Degree of channel inventory and wholesaler demand signals

Those financial inputs are not available in the prompt, so the article cannot quantify revenue exposure.

Key takeaways

• VIIBRYD’s market dynamics have been dominated by managed care economics: net pricing, rebate contracting, and formulary tiering that steadily erode branded utilization as lower-cost alternatives stabilize share.
• The product’s branded lifecycle profile aligns with long-run antidepressant market pressure, not durable growth.
• Generic and competitive risk is structurally high for small-molecule antidepressants once broad protections are exhausted, making sustained share retention difficult.
• A patent-exclusivity and Orange Book status map cannot be accurately produced from the provided information, and litigation impact cannot be reliably attributed without docket- and Orange-Book-level data.

FAQs

1) What are the main drivers of VIIBRYD net sales decline in managed care?
Formulary displacement, rebate pressure, and higher switching rates to preferred generics.

2) Does VIIBRYD face generic competition risk despite potential remaining patents?
Yes, because small-molecule products can transition quickly once any enforceable protection gaps exist, though the exact timing depends on Orange Book and claim scope.

3) How do antidepressant PBM formularies typically affect branded utilization of VIIBRYD?
They favor preferred tiers that maximize net cost efficiency, pushing branded products toward narrower access unless they achieve favorable contracting.

4) What label or tolerability considerations do clinicians use when keeping patients on VIIBRYD?
Side-effect profile comparisons and historical patient response often drive continuity, but payer coverage can override prescribing preferences.

5) What signals indicate when branded CNS products like VIIBRYD are near structural share loss?
Rapid changes in formulary status, increasing prior authorization denials, and accelerating utilization drift toward preferred generics.

References

1. FDA Orange Book (Drugs@FDA and Approved Drug Products with Therapeutic Equivalence Evaluations). U.S. Food and Drug Administration.
2. FDA. Drugs@FDA: VIIBRYD (vilazodone) product information. U.S. Food and Drug Administration.

DrugChatter Q&A for VIIBRYD

How much is viibryd without insurance?
Viibryd generic availability?
Viibryd mechanism of action?
How much does viibryd cost?
Does viibryd have a generic?